tiprankstipranks
Advertisement
Advertisement

IKT Stock Latest News

Inhibikase Therapeutics: Buy Rating Reiterated on Advancing Phase 3 PAH Program and Robust IP, Price Target Maintained at $8
RatingsInhibikase Therapeutics: Buy Rating Reiterated on Advancing Phase 3 PAH Program and Robust IP, Price Target Maintained at $8
5d ago
IKT
Analyst Flags High Risk in Inhibikase Therapeutics Stock, Urges Investors to Review 2025 Form 10-K Risk Factors
PremiumCompany Announcements
Analyst Flags High Risk in Inhibikase Therapeutics Stock, Urges Investors to Review 2025 Form 10-K Risk Factors
17d ago
IKT
Inhibikase Advances IKT-001 Into Adaptive Phase 3 Trial for Pulmonary Arterial Hypertension
PremiumCompany Announcements
Inhibikase Advances IKT-001 Into Adaptive Phase 3 Trial for Pulmonary Arterial Hypertension
19d ago
IKT
Buy Rating on IKT-001: De-Risked Late-Stage PAH Program with Adaptive Phase 3 Design and Solid Financial Runway
PremiumRatings
Buy Rating on IKT-001: De-Risked Late-Stage PAH Program with Adaptive Phase 3 Design and Solid Financial Runway
2M ago
IKT
Inhibikase Therapeutics: Phase 3 IKT-001 PAH Program and De-Risked Imatinib-Based Efficacy Drive Buy Rating and $8 Target
PremiumRatings
Inhibikase Therapeutics: Phase 3 IKT-001 PAH Program and De-Risked Imatinib-Based Efficacy Drive Buy Rating and $8 Target
2M ago
IKT
Inhibikase Begins Pivotal Phase 3 Trial in PAH
PremiumCompany AnnouncementsInhibikase Begins Pivotal Phase 3 Trial in PAH
2M ago
8K
IKT
Inhibikase Therapeutics enrolls first patient in IMPROVE-PAH study
Premium
The Fly
Inhibikase Therapeutics enrolls first patient in IMPROVE-PAH study
2M ago
IKT
IKT Upcoming Earnings Report: What to Expect?
Premium
Pre-Earnings
IKT Upcoming Earnings Report: What to Expect?
2M ago
IKT
Inhibikase Therapeutics initiated with a Buy at Ladenburg
PremiumThe Fly
Inhibikase Therapeutics initiated with a Buy at Ladenburg
3M ago
IKT
Inhibikase Therapeutics initiated with a Buy at Ladenburg
PremiumThe Fly
Inhibikase Therapeutics initiated with a Buy at Ladenburg
3M ago
IKT
Buy Rating on Inhibikase Therapeutics Driven by Rival PAH Setback and Pivotal Phase 3 IMPROVE-PAH Trial for IKT-001
PremiumRatings
Buy Rating on Inhibikase Therapeutics Driven by Rival PAH Setback and Pivotal Phase 3 IMPROVE-PAH Trial for IKT-001
3M ago
IKT
Bank of America Predicts Up to 240% Jump for These 2 ‘Strong Buy’ Stocks
PremiumMarket News
Bank of America Predicts Up to 240% Jump for These 2 ‘Strong Buy’ Stocks
3M ago
IKT
WVE
Inhibikase Therapeutics initiated with a Buy at BofA
PremiumThe FlyInhibikase Therapeutics initiated with a Buy at BofA
4M ago
IKT
Dynavax, Inhibikase and More: Stocks Trending by Analysts
Premium
Weekend Updates
Dynavax, Inhibikase and More: Stocks Trending by Analysts
5M ago
IKT
DVAX
Inhibikase Therapeutics: Late-Stage IKT-001 PAH Program and De-Risked 505(b)(2) Pathway Support Buy Rating and $8 Target
Premium
Ratings
Inhibikase Therapeutics: Late-Stage IKT-001 PAH Program and De-Risked 505(b)(2) Pathway Support Buy Rating and $8 Target
5M ago
IKT
Inhibikase Updates ATM Equity Program to Raise Capital
PremiumCompany Announcements
Inhibikase Updates ATM Equity Program to Raise Capital
5M ago
8K
IKT
Inhibikase Therapeutics initiated with an Overweight at Cantor Fitzgerald
PremiumThe Fly
Inhibikase Therapeutics initiated with an Overweight at Cantor Fitzgerald
6M ago
IKT
Inhibikase Therapeutics: Advancing IKT-001 to Revolutionize PAH Treatment and Capture Multi-Billion-Dollar Market
PremiumRatings
Inhibikase Therapeutics: Advancing IKT-001 to Revolutionize PAH Treatment and Capture Multi-Billion-Dollar Market
6M ago
IKT
Inhibikase Therapeutics Reports Q3 2025 Financials and Progress
PremiumCompany Announcements
Inhibikase Therapeutics Reports Q3 2025 Financials and Progress
6M ago
IKT
Inhibikase Therapeutics Announces $93.6 Million Stock Offering
PremiumCompany AnnouncementsInhibikase Therapeutics Announces $93.6 Million Stock Offering
6M ago
8K
IKT
Inhibikase Therapeutics 46.1M share Spot Secondary priced at $1.45
Premium
The Fly
Inhibikase Therapeutics 46.1M share Spot Secondary priced at $1.45
6M ago
IKT
Inhibikase Therapeutics TBA Spot Secondary; reoffered at $1.45
Premium
The Fly
Inhibikase Therapeutics TBA Spot Secondary; reoffered at $1.45
6M ago
IKT

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >